Lung

Lung cancer is the leading cause of cancer-related deaths in the United States.¹ You can trust our testing expertise to help detect and manage lung cancer. We deliver powerfully exceptional diagnosis, prognosis, treatment, and monitoring services for your patients throughout their cancer journey.

The AmeriPath^® national network of board-certified pathologists provides comprehensive pathology services utilizing state-of-the-art technologies, including immunohistochemistry and molecular diagnostics.

We are an industry leader in breast tumor pathology expertise. Combined with our comprehensive test menu and advanced technology, our expertise helps ensure you receive fast and clear diagnostic, prognostic, and therapeutic information promptly.

Quest Diagnostics maintains an up-to-date and robust selection of immunohistochemical stains to gather diagnostic insight for the patient, including companion diagnostics that can be used to inform downstream treatment selection. Examples of our extensive menu are provided below.

PD-L1 is a protein that protects normal cells from destruction when T cells are activated. Some cancer cells take advantage of this protective role by highly expressing PD-L1 to evade the immune system. 

The HER2 (also known as ERBB2 or HER-2/neu) protooncogene encodes a tyrosine kinase receptor that is a member of the epidermal growth factor receptor (EGFR) family. HER2 status can be assessed by detecting either protein overexpression with immunohistochemistry (IHC) or gene amplification with in situ hybridization (ISH). HER2 status determines patient eligibility for HER2-targeted therapy.

LiquidSEQ™ is a liquid biopsy for treatment selection. It provides a comprehensive molecular profile—including 523 genes associated with a broad spectrum of solid tumor cancers—that assesses the DNA only for single nucleotide variants (SNVs), copy number variants (CNVs), and fusions along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB). This panel would be used if the clinician desires a comprehensive analysis of a patient’s genetic profile from the patient’s blood in the event tissue is not available or insufficient. This panel contains clinically actionable genes as well as emerging genes.

Precision medicine is an emerging approach for disease prevention and treatment that takes individual variability into account. This next-generation sequencing (NGS) panel, along with the computational resources and tools that process and analyze the data, allows the characterization of individual patients and tumor types. Guidelines exist for using results from many of these genes for selection of FDA-approved therapies.

Solid TumorSEQ™ provides a comprehensive molecular profile from biopsy tissue, including 523 genes associated with a broad spectrum of solid tumor cancers, and assesses the DNA and RNA for SNVs, CNVs, fusions, and splice variants along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB). This panel would be used if a clinician desires a comprehensive analysis of a patient’s genetic profile from tumor tissue. This panel contains clinically actionable genes as well as emerging genes chosen based on alignment to guidelines, drug labels and clinical trials across multiple solid tumor types.

LungSEQ® 

The Quest Advanced Oncology LungSEQ Concurrent Panel, part of our comprehensive solution for lung cancer diagnostics, is a disease-targeted NGS panel. We’ve developed these and other decision-support tools to help physicians create a treatment plan for navigating within standard of care and clinical trial options, based on the mutations found in the patient’s tumor.
 
The LungSEQ Concurrent Panel simultaneously performs NGS and FISH, and includes KRAS G12C, a recently discovered actionable biomarker for some types of lung cancer.

Haystack MRD^®

Sensitivity matters when looking for the smallest evidence of disease, such as residual disease after surgery or response to adjuvant chemotherapy. Haystack MRD^® minimizes false negatives by detecting ultralow levels of ctDNA, providing confidence in therapeutic decisions.²